Evidence map›Paper›PMID 29440737›Full record

ArticleBone marrow transplantation2018

BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant.

F Marchesi, S Capria, D Giannarelli, S M Trisolini, M Ansuinelli, M D Caputo, A Serrao, S Gumenyuk, D Renzi, L Pupo and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 1 country.

F MarchesiHematology and Stem Cell Transplant Unit, Experimental and Clinical Oncology Department, IRCCS Regina Elena National Cancer Institute, Rome, Italy. francesco.marchesi@ifo.gov.it.
S CapriaHematology Unit, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, La Sapienza University, Rome, Italy.
D GiannarelliBiostatistical Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
S M TrisoliniHematology Unit, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, La Sapienza University, Rome, Italy.
M AnsuinelliHematology Unit, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, La Sapienza University, Rome, Italy.
M D CaputoHematology Unit, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, La Sapienza University, Rome, Italy.
A SerraoHematology Unit, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, La Sapienza University, Rome, Italy.
S GumenyukHematology and Stem Cell Transplant Unit, Experimental and Clinical Oncology Department, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
D RenziHematology and Stem Cell Transplant Unit, Experimental and Clinical Oncology Department, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
L PupoHematology Unit, Tor Vergata University, Rome, Italy.
F PalombiHematology and Stem Cell Transplant Unit, Experimental and Clinical Oncology Department, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
I ProvenzanoHematology Unit, Tor Vergata University, Rome, Italy.
A Di RoccoHematology Unit, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, La Sapienza University, Rome, Italy.
F PisaniHematology and Stem Cell Transplant Unit, Experimental and Clinical Oncology Department, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
A RomanoHematology and Stem Cell Transplant Unit, Experimental and Clinical Oncology Department, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
A SpadeaHematology and Stem Cell Transplant Unit, Experimental and Clinical Oncology Department, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
E PapaHematology and Stem Cell Transplant Unit, Experimental and Clinical Oncology Department, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
M CanforaScientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
M CantonettiHematology Unit, Tor Vergata University, Rome, Italy.
A MengarelliHematology and Stem Cell Transplant Unit, Experimental and Clinical Oncology Department, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · ITPoliclinico Umberto I · ITUniversity of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarmustineCytarabineEtoposideFemaleHematopoietic Stem Cell TransplantationHumansMaleMelphalanMiddle AgedRetrospective StudiesTransplantation, AutologousTransplantation ConditioningCarmustineCytarabineEtoposideMelphalan

Identifiers

PMID29440737
OpenAlexW2793583306

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.